Unnamed: 0,title,date,stock,sentiment
895466.0,10 Biggest Price Target Changes For Monday,2020-06-08 08:35:00-04:00,NERV,neutral
895467.0,"HC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to $10",2020-06-08 06:37:00-04:00,NERV,negative
895468.0,Hearing JMP Securities is Reinstating its Market Outperform Rating on Minerva Neurosciences with a $9 Price Target,2020-06-05 13:34:00-04:00,NERV,positive
895469.0,71 Biggest Movers From Yesterday,2020-06-02 04:39:00-04:00,NERV,neutral
895470.0,48 Stocks Moving In Monday's Mid-Day Session,2020-06-01 12:34:00-04:00,NERV,neutral
895471.0,Mid-Morning Market Update: Markets Edge Higher; Zynga To Buy Mobile Game Developer Peak For $1.8B,2020-06-01 10:18:00-04:00,NERV,neutral
895472.0,26 Stocks Moving in Monday's Pre-Market Session,2020-06-01 07:02:00-04:00,NERV,neutral
895473.0,72 Biggest Movers From Friday,2020-06-01 04:53:00-04:00,NERV,neutral
895474.0,Mid-Afternoon Market Update: U.S. Stocks Turn Positive; Crude Oil Surges Over 5%,2020-05-29 15:10:00-04:00,NERV,neutral
895475.0,50 Stocks Moving In Friday's Mid-Day Session,2020-05-29 12:15:00-04:00,NERV,neutral
895476.0,Mid-Day Market Update: Canopy Growth Slides After Q4 Results; Sonoma Pharmaceuticals Shares Surge,2020-05-29 12:00:00-04:00,NERV,positive
895477.0,"Minerva Shares Halted On Third Circuit Breaker Of The Day, Stock Down 81.2% For Session",2020-05-29 10:53:00-04:00,NERV,positive
895478.0,Mid-Morning Market Update: Markets Open Lower; Big Lots Beats Q1 Estimates,2020-05-29 10:22:00-04:00,NERV,negative
895479.0,"Minerva Shares Resumed Trade, Fall 67%, Halted On Circuit Breaker",2020-05-29 09:52:00-04:00,NERV,positive
895480.0,UPDATE: Minerva Schizophrenia Phase 3 Did Not Meet Primary Endpoint,2020-05-29 09:23:00-04:00,NERV,neutral
895481.0,Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia; Shares Still Halted,2020-05-29 09:22:00-04:00,NERV,negative
895482.0,Minerva Neurosciences Halted Due To News Pending,2020-05-29 09:19:00-04:00,NERV,neutral
895483.0,Minerva Neurosciences Option Alert: Jul 17 $22.5 Calls at the Ask: 2939 @ $4.0 vs 40 OI; Ref=$13.585,2020-05-28 15:21:00-04:00,NERV,positive
895484.0,48 Stocks Moving In Thursday's Mid-Day Session,2020-05-28 12:28:00-04:00,NERV,neutral
895485.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,NERV,positive
895486.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,NERV,neutral
895487.0,Stocks That Hit 52-Week Highs On Friday,2020-05-22 10:31:00-04:00,NERV,neutral
895488.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,NERV,neutral
895489.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,NERV,positive
895490.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,NERV,neutral
895491.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,NERV,positive
895492.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-13 10:35:00-04:00,NERV,neutral
895493.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,NERV,neutral
895494.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,NERV,neutral
895495.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,NERV,negative
895496.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,NERV,neutral
895497.0,Stocks That Hit 52-Week Highs On Friday,2020-05-08 10:32:00-04:00,NERV,neutral
895498.0,"The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda",2020-05-08 07:59:00-04:00,NERV,neutral
895499.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,NERV,positive
895500.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-05 10:48:00-04:00,NERV,neutral
895501.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,NERV,positive
895502.0,Stocks That Hit 52-Week Highs On Monday,2020-05-04 10:35:00-04:00,NERV,neutral
895503.0,Minerva Neurosciences Q1 EPS $(0.310) Beats $(0.360) Estimate,2020-05-04 07:31:00-04:00,NERV,neutral
895504.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,NERV,neutral
895505.0,136 Biggest Movers From Yesterday,2020-03-13 05:20:00-04:00,NERV,neutral
895506.0,90 Stocks Moving In Thursday's Mid-Day Session,2020-03-12 12:21:00-04:00,NERV,neutral
895507.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,NERV,negative
895508.0,Mid-Day Market Update: Crude Oil Down Over 5%; Alpha Pro Tech Shares Spike Higher,2020-03-12 12:07:00-04:00,NERV,negative
895509.0,Mid-Morning Market Update: Markets Open Lower After Trump Bans Travel From Europe,2020-03-12 10:15:00-04:00,NERV,negative
895510.0,Minerva Neurosciences Q4 EPS $(0.77) Down From $(0.34) YoY,2020-03-09 07:32:00-04:00,NERV,neutral
895511.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,NERV,negative
895512.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,NERV,negative
895513.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,NERV,neutral
895514.0,Minerva Neurosciences Reports Completion Of Patient Enrollment In Phase 3 Trial Of Roluperidone For Treatment Of Negative Symptoms In Schizophrenia,2020-02-05 08:08:00-05:00,NERV,negative
895515.0,Minerva Neurosciences Option Alert: Jul 17 $12.5 Calls at the Ask: 2980 @ $4.1 vs 191 OI; Earnings 3/10 Before Open [est] Ref=$8.05,2020-01-27 12:41:00-05:00,NERV,positive
895516.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,NERV,neutral
895517.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,NERV,negative
895518.0,76 Biggest Movers From Yesterday,2020-01-17 04:54:00-05:00,NERV,neutral
895519.0,Minerva Neurosciences Says it Expects to Complete Enrollment for its Phase 3 Trial of Roluperidone in January,2020-01-06 08:19:00-05:00,NERV,neutral
895520.0,51 Biggest Movers From Tuesday,2019-12-26 05:14:00-05:00,NERV,neutral
895521.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,NERV,neutral
895522.0,60 Biggest Movers From Friday,2019-12-23 05:37:00-05:00,NERV,neutral
895523.0,40 Stocks Moving In Friday's Mid-Day Session,2019-12-20 12:07:00-05:00,NERV,neutral
895524.0,68 Biggest Movers From Yesterday,2019-12-20 04:34:00-05:00,NERV,neutral
895525.0,Mid-Afternoon Market Update: Rite Aid Jumps On Upbeat Earnings; Apogee Enterprises Shares Slide,2019-12-19 14:27:00-05:00,NERV,positive
895526.0,46 Stocks Moving In Thursday's Mid-Day Session,2019-12-19 12:51:00-05:00,NERV,neutral
895527.0,Mid-Day Market Update: Dow Rises Over 100 Points; Minerva Neurosciences Shares Plunge,2019-12-19 12:04:00-05:00,NERV,positive
895528.0,"JMP Securities Maintains Market Outperform on Minerva Neurosciences, Lowers Price Target to $18",2019-12-19 10:02:00-05:00,NERV,positive
895529.0,Minerva Neurosciences Shelves Depression Drug Study After Failed Mid-Stage Trial,2019-12-19 09:35:00-05:00,NERV,negative
895530.0,36 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-12-19 08:28:00-05:00,NERV,neutral
895531.0,28 Stocks Moving in Thursday's Pre-Market Session,2019-12-19 08:13:00-05:00,NERV,neutral
895532.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,NERV,negative
895533.0,"H.C. Wainwright Reiterates Buy on Minerva Neurosciences, Lowers Price Target to $20",2019-12-19 07:13:00-05:00,NERV,negative
895534.0,Minerva Shares To Resume Trade At 4:35 p.m. EST,2019-12-18 16:11:00-05:00,NERV,positive
895535.0,Minerva Neurosciences Announces Phase 2b Trial Of MIN-117 In Major Depressive Disorder Did Not Meet PRimary And Key Secondary Endpoints; Says Has No Plans For Further Clinical Development In MDD,2019-12-18 16:06:00-05:00,NERV,negative
895536.0,Minerva Biosciences Shares Halted News Pending,2019-12-18 16:01:00-05:00,NERV,positive
895537.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,NERV,neutral
895538.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,NERV,neutral
895539.0,77 Biggest Movers From Yesterday,2019-11-20 04:57:00-05:00,NERV,neutral
895540.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-11-19 12:45:00-05:00,NERV,neutral
895541.0,Minerva Neurosciences Q3 EPS $(0.36) Beats $(0.37) Estimate,2019-11-04 07:34:00-05:00,NERV,neutral
895542.0,27 Stocks Moving In Thursday's Mid-Day Session,2019-10-31 11:51:00-04:00,NERV,neutral
895543.0,Stocks That Hit 52-Week Lows On Monday,2019-10-21 11:12:00-04:00,NERV,negative
895544.0,46 Biggest Movers From Yesterday,2019-10-03 05:05:00-04:00,NERV,neutral
895545.0,52 Biggest Movers From Yesterday,2019-10-02 04:22:00-04:00,NERV,neutral
895546.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Roan Resources Shares Jump,2019-10-01 14:33:00-04:00,NERV,negative
895547.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-10-01 11:59:00-04:00,NERV,neutral
895548.0,Mid-Day Market Update: Dow Falls Over 200 Points; Constellation Pharmaceuticals Shares Spike Higher,2019-10-01 11:57:00-04:00,NERV,positive
895549.0,Mid-Morning Market Update: Markets Open Lower; McCormick Earnings Top Expectations,2019-10-01 10:16:00-04:00,NERV,negative
895550.0,Minerva Neurosciences shares are trading lower after the company delayed the results for its Schizophrenia drug.,2019-10-01 09:06:00-04:00,NERV,negative
895551.0,23 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-01 08:24:00-04:00,NERV,neutral
895552.0,Minerva Neurosciences Announces 384 Patients Of A Total Target Of 501 Have Been Enrolled In Phase 3 Trial Of Roluperidone; Anticipates Top-Line Results To Be Available In 1H 2020,2019-10-01 07:31:00-04:00,NERV,neutral
895553.0,"Benzinga's Top Upgrades, Downgrades For September 25, 2019",2019-09-25 10:04:00-04:00,NERV,positive
895554.0,"Chardan Capital Initiates Coverage On Minerva Neurosciences with Buy Rating, Announces $17 Price Target",2019-09-25 06:06:00-04:00,NERV,neutral
895555.0,Catalent And Minerva Neurosciences Enter Commercial Supply Agreement For Schizophrenia Drug Roluperidone,2019-09-24 09:04:00-04:00,NERV,positive
895556.0,"Benzinga's Top Upgrades, Downgrades For September 18, 2019",2019-09-18 10:54:00-04:00,NERV,positive
895557.0,William Blair Initiates Coverage On Minerva Neurosciences with Outperform Rating,2019-09-18 08:10:00-04:00,NERV,neutral
895558.0,71 Biggest Movers From Yesterday,2019-09-12 05:33:00-04:00,NERV,neutral
895559.0,30 Stocks Moving in Monday's Pre-Market Session,2019-09-09 07:57:00-04:00,NERV,neutral
895560.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,NERV,neutral
895561.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,NERV,neutral
895562.0,Minerva Neurosciences Q2 EPS $(0.32) Beats $(0.42) Estimate,2019-08-05 07:20:00-04:00,NERV,neutral
895563.0,48 Biggest Movers From Wednesday,2019-07-05 05:08:00-04:00,NERV,neutral
895564.0,51 Biggest Movers From Yesterday,2019-06-26 05:53:00-04:00,NERV,neutral
895565.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-06-25 12:44:00-04:00,NERV,neutral
895566.0,"A Look At Benzinga Pro's Most-Searched Tickers For June 25, 2019",2019-06-25 12:07:00-04:00,NERV,neutral
895567.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, June 25 2019",2019-06-25 10:26:00-04:00,NERV,positive
895568.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-06-25 08:04:00-04:00,NERV,neutral
895569.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,NERV,neutral
895570.0,Mid-Afternoon Market Update: Crude Oil Up 1%; Minerva Neurosciences Shares Spike Higher,2019-06-24 14:57:00-04:00,NERV,negative
895571.0,40 Stocks Moving In Monday's Mid-Day Session,2019-06-24 12:35:00-04:00,NERV,neutral
895572.0,Mid-Day Market Update: PCM Jumps Following Acquisition News; 360 Finance Shares Slide,2019-06-24 12:10:00-04:00,NERV,positive
895573.0,Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial,2019-06-24 11:00:00-04:00,NERV,positive
895574.0,Mid-Morning Market Update: Markets Edge Higher; Eldorado To Buy Caesars For $17.3B,2019-06-24 10:09:00-04:00,NERV,neutral
895575.0,Minerva Neurosciences shares are trading higher after the company announced that its Phase 2B trial for the clinical trial of Seltorexant achieved its primary and key secondary objectives.,2019-06-24 08:30:00-04:00,NERV,positive
895576.0,Minerva Neurosciences and Del Frisco's to Resume Trading at 8:00am ET,2019-06-24 07:57:00-04:00,NERV,neutral
895577.0,Minerva Neurosciences Cmn Shares To Resume Trade At 8:00 a.m. EDT,2019-06-24 07:38:00-04:00,NERV,positive
895578.0,Minerva Neurosciences Achieves Primary and Key Secondary Objectives in its Phase 2B Clinical Trial of Seltorexant,2019-06-24 07:36:00-04:00,NERV,neutral
895579.0,"Minerva Neurosciences Halted, News Pending",2019-06-24 07:27:00-04:00,NERV,neutral
895580.0,"The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy",2019-06-21 07:18:00-04:00,NERV,negative
895581.0,"The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale",2019-06-18 07:31:00-04:00,NERV,neutral
895582.0,"The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes",2019-06-13 07:44:00-04:00,NERV,negative
895583.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,NERV,neutral
895584.0,"Benzinga's Top Upgrades, Downgrades For May 31, 2019",2019-05-31 09:09:00-04:00,NERV,positive
895585.0,"H.C. Wainwright Initiates Coverage On Minerva Neurosciences with Buy Rating, Announces $22 Price Target",2019-05-31 07:47:00-04:00,NERV,neutral
895586.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,NERV,positive
895587.0,"The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice",2019-05-24 07:44:00-04:00,NERV,neutral
895588.0,"The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut",2019-05-23 07:37:00-04:00,NERV,neutral
895589.0,Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug,2019-05-13 11:01:00-04:00,NERV,negative
895590.0,Minerva Neurosciences Announces 'Positive' Top Line Results in Phase 2b Clinical Trial With Seltorexant in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs,2019-05-13 08:15:00-04:00,NERV,negative
895591.0,Minerva Neurosciences Highlights Presentation Pre-Clinical Data Suggesting A Mechanistic Role Of Roluperidone In Addressing Negative Symptoms Of Schizophrenia,2019-04-11 08:31:00-04:00,NERV,negative
895592.0,"Minerva Neurosciences, Inc Q4 EPS $(0.34) Beats $(0.36) Estimate",2019-03-12 06:43:00-04:00,NERV,neutral
895593.0,"Earnings Scheduled For March 12, 2019",2019-03-12 04:16:00-04:00,NERV,neutral
895594.0,"Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.",2019-03-06 11:59:00-05:00,NERV,negative
895595.0,Minerva Neurosciences Announces New Patent Application For MIN-117 Related To Broad Effect On Pain,2018-11-28 08:03:00-05:00,NERV,negative
895596.0,Minerva Neurosciences Announces Results Of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered At Supra-Therapeutic Doses In Healthy Volunteers; Says Doses Up To 256 Miligrams Appear Safe And Will Tolerated,2018-11-19 08:09:00-05:00,NERV,positive
895597.0,"Minerva Neurosciences, Inc - Common Stock Q3 EPS $(0.31) Beats $(0.38) Estimate",2018-11-05 07:34:00-05:00,NERV,neutral
895598.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,NERV,neutral
895599.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,NERV,neutral
895600.0,"Stocks Which Set New 52-Week High Yesterday, September 24th",2018-09-25 09:06:00-04:00,NERV,neutral
895601.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,NERV,negative
895602.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,NERV,neutral
895603.0,"Stocks Which Set New 52-Week High Yesterday, September 13th",2018-09-14 09:26:00-04:00,NERV,neutral
895604.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,NERV,neutral
895605.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,NERV,neutral
895606.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,NERV,neutral
895607.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,NERV,neutral
895608.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,NERV,negative
895609.0,Minerva Neurosciences Reports Findings From Recent Pre-Clinical Study Which Provided Evidence Of Effect Of MIN-101 On Brain-Derived Neurotrophic Factor,2018-08-22 08:31:00-04:00,NERV,neutral
895610.0,Minerva Neurosciences Q2 EPS $(0.32) Beats $(0.38) Estimate,2018-08-02 09:34:00-04:00,NERV,neutral
895611.0,Minerva Neurosciences Elects Jeryl Hilleman To Board Of Directors,2018-07-17 16:06:00-04:00,NERV,neutral
895612.0,48 Biggest Movers From Yesterday,2018-05-18 04:54:00-04:00,NERV,neutral
895613.0,32 Stocks Moving In Thursday's Mid-Day Session,2018-05-17 12:34:00-04:00,NERV,neutral
895614.0,Minerva Neurosciences Shares Up 17.7% Premarket After Journal of Clinical Psychiatry Published Positive Results Of Cognitive Performance From Phase 2B Trial Of Roluperidone In Schizophrenia Patients,2018-05-17 09:10:00-04:00,NERV,positive
895615.0,"Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia",2018-05-17 08:03:00-04:00,NERV,neutral
895616.0,"Minerva Neurosciences, Inc - Common Stock Q1 EPS $(0.32) Misses $(0.28) Estimate",2018-05-03 07:48:00-04:00,NERV,negative
895617.0,Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder,2018-04-09 08:33:00-04:00,NERV,negative
895618.0,"Minerva Neurosciences Reports Q4 EPS $0.00 vs $(0.38) Est., No Sales",2018-03-12 07:35:00-04:00,NERV,negative
895619.0,"Earnings Scheduled For March 12, 2018",2018-03-12 04:35:00-04:00,NERV,neutral
895620.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-02-21 08:02:00-05:00,NERV,neutral
895621.0,Minerva Neurosciences Reports Enrollment Of First Patient In Phase 2b Trial Comparing MIN-202 vs Quetiapine,2017-12-21 08:04:00-05:00,NERV,neutral
895622.0,Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant  Versus Quetiapine,2017-12-21 08:01:00-05:00,NERV,neutral
895623.0,Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia,2017-12-19 08:02:00-05:00,NERV,negative
895624.0,Minerva Neurosciences Names Richard Russell Pres,2017-12-11 16:31:00-05:00,NERV,neutral
895625.0,Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant in Patients With Insomnia Disorder,2017-12-06 08:30:00-05:00,NERV,negative
895626.0,Minerva Neurosciences Reports Q3 EPS $(0.28) vs $(0.27) Est.,2017-11-06 07:32:00-05:00,NERV,neutral
895627.0,Minerva Neurosciences Reports Enrollment Of Initial Patient In Phase 2B Trial Of MIN-202,2017-09-05 08:02:00-04:00,NERV,neutral
895628.0,18 Biggest Mid-Day Gainers For Friday,2017-09-01 12:07:00-04:00,NERV,neutral
895629.0,"Benzinga's Top Upgrades, Downgrades For September 1, 2017",2017-09-01 09:21:00-04:00,NERV,positive
895630.0,Minerva Neurosciences Reports European Commission Approval Of Amendment Of MIN-202 Agreement With Janssen,2017-08-25 08:32:00-04:00,NERV,positive
895631.0,Minerva Neurosciences Reports Q2 EPS $(0.27) vs $(0.34) Est.,2017-08-03 07:55:00-04:00,NERV,neutral
895632.0,Minerva Neurosciences To Offer 5M Shares Common Stock,2017-06-27 16:13:00-04:00,NERV,positive
895634.0,"Minerva Neurosciences Q1 EPS $(0.30) vs $(0.30) Est, No Sales",2017-05-04 08:29:00-04:00,NERV,negative
895635.0,Minerva Neurosciences Announces Institutional Investors Have Exercised Warrants With Respect To 1.6M Shares At Price Of $5.772/Share Since 12/31/16; Warrants Have Now Expired,2017-03-21 16:11:00-04:00,NERV,positive
895636.0,Minerva Neurosciences Reports Certain Investors in March 2015 Private Placement Exercised Warrants; Gross Proceeds to Co of ~$8.2M,2017-03-21 06:35:00-04:00,NERV,negative
895637.0,Minerva Neurosciences Reports Q4 EPS $(0.27) vs $(0.25) Est.,2017-03-13 07:32:00-04:00,NERV,neutral
895638.0,15 Biggest Mid-Day Gainers For Monday,2017-03-06 12:56:00-05:00,NERV,neutral
895639.0,"Benzinga's Top Upgrades, Downgrades For March 6, 2017",2017-03-06 09:48:00-05:00,NERV,positive
895640.0,"Jefferies Initiates Coverage On Minerva Neurosciences With Buy, Announces $17 Price Target",2017-03-06 06:43:00-05:00,NERV,neutral
895641.0,Minerva Neurosciences Reports Added Data Analyses from Phase IIb Trial of MIN-101 in Schizophrenia Highlight Benefit in Multiple Measurements of Cognitive Function,2017-01-20 08:31:00-05:00,NERV,positive
895642.0,"Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer",2016-12-20 08:33:00-05:00,NERV,neutral
895643.0,Jefferies London Health Care Conference Continues Today,2016-11-17 10:14:00-05:00,NERV,positive
895644.0,"Minerva Neurosciences Q3 EPS $(0.24) vs $(0.21) Est, No Revenue",2016-11-03 07:35:00-04:00,NERV,negative
895645.0,Minerva Neurosciences Reports Q3 EPS $(0.24) vs. Est. $(0.21),2016-11-03 07:30:00-04:00,NERV,neutral
895646.0,15 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-27 07:25:00-04:00,NERV,neutral
895647.0,"Minerva Reports Positive Data from Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia: 'Data show continuous improvement in negative symptoms, stable positive symptoms and extended safety profile'",2016-10-26 08:32:00-04:00,NERV,positive
895648.0,Minerva Neurosciences Reports Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meeting,2016-10-13 08:30:00-04:00,NERV,positive
895649.0,Index Venture Associates Report 7.3% Stake In Minerva Neurosciences,2016-09-27 16:31:00-04:00,NERV,neutral
895650.0,"UPDATE: Minerva Reports FDA Acceptance of INDA for MIN-117, Last Patient Completed Extension Phase of Phase IIb Trial of MIN-101",2016-09-26 08:32:00-04:00,NERV,positive
895651.0,"Minerva Neurosciences Reports Update on MIN-101, MIN-117 Programs",2016-09-26 08:32:00-04:00,NERV,neutral
895652.0,22 Stocks Moving In Wednesday's Pre-Market Session,2016-08-10 08:25:00-04:00,NERV,neutral
895653.0,Minerva Neurosciences Reports Q2 EPS $(0.18) vs. Est. $(0.30),2016-08-04 07:56:00-04:00,NERV,neutral
895654.0,"Director Kupfer Buys 55,635 Shares of Minerva Neurosciences @ $10.84/Share -Form 4",2016-06-21 17:02:00-04:00,NERV,positive
895655.0,Minerva Neurosciences Prices 5.263M Shares At $9.50/Share,2016-06-14 09:05:00-04:00,NERV,positive
895656.0,Minerva Neurosciences Reports Proposed Public Offering of Common Stock,2016-06-13 16:02:00-04:00,NERV,neutral
895657.0,"Minerva Neurosciences Continues To Rally, Up 300% In A Week",2016-06-01 15:50:00-04:00,NERV,neutral
895658.0,15 Stocks Moving In Friday's Pre-Market Session,2016-05-27 08:17:00-04:00,NERV,neutral
895659.0,Mid-Afternoon Market Update: Abercrombie & Fitch Slides On Disappointing Results; Minerva Neurosciences Shares Spike Higher,2016-05-26 14:32:00-04:00,NERV,negative
895660.0,Minverva Biosciences Surrenders Some Of Earlier Gains,2016-05-26 13:17:00-04:00,NERV,positive
895661.0,Mid-Day Market Update: Dollar Tree Surges Following Earnings Beat; OvaScience Shares Drop,2016-05-26 12:09:00-04:00,NERV,neutral
895662.0,Minerva Neurosciences Shares Jump 200% On Positive Results From Phase IIB Study of MIN-101 Monotherapy,2016-05-26 10:39:00-04:00,NERV,positive
895663.0,Mid-Morning Market Update: Markets Mostly Flat; Dollar General Profit Beats Expectations,2016-05-26 10:04:00-04:00,NERV,positive
895664.0,Minerva Neurosciences Spikes to High of $10.38 Following  MIN-117  Results,2016-05-26 08:48:00-04:00,NERV,neutral
895665.0,Minerva Neurosciences Shares Spiking Higher,2016-05-26 08:45:00-04:00,NERV,positive
895666.0,Minerva Neurosciences To Resume Trade At 8:45am ET,2016-05-26 08:26:00-04:00,NERV,neutral
895667.0,"UPDATE: Minerva Neurosciences Says No Unexpected Adverse Events Were Reported, MIN-117 Not Associated With Cognitive Impairment, Sexual Dysfunction, Suicidal Ideation Or Weight Gain",2016-05-26 08:17:00-04:00,NERV,negative
895668.0,"UPDATE: Minerva on MIN-117 Trial Reports 'Reduction in depressive symptoms demonstrated,' 'Good tolerability and safety profile observed,' 'Positive effect on sleep architecture shown'",2016-05-26 08:16:00-04:00,NERV,positive
895669.0,"Minerva Reports Results in Phase IIA Trial of MIN-117: Meets Both Primary, Secondary Endpoints",2016-05-26 08:15:00-04:00,NERV,neutral
895670.0,"Minerva Neurosciences Min-101 Monotherapy Showed Statistically Significant Benefits Over Placebo In Improving Negative Symptoms As Well As PANSS Psychopathology Subscale, BNSS Total Score and CGI-S & CGI-I",2016-05-26 08:04:00-04:00,NERV,positive
895671.0,"MInerva Neurosciences Meets Primary, Secondary Endpoint In MIN-101 Monotherapy",2016-05-26 08:02:00-04:00,NERV,neutral
895672.0,Minerva Neurosciences Shares Halted News Pending,2016-05-26 07:57:00-04:00,NERV,positive
895673.0,"Jefferies Assumes Minerva Neurosciences at Buy, Announces $10.00 PT",2016-05-12 07:15:00-04:00,NERV,neutral
895674.0,Minerva Neurosciences Reports Q1 EPS $(0.29) vs. Est. $(0.33),2016-05-03 07:33:00-04:00,NERV,neutral
895675.0,"Minerva Neurosciences To Sell Dr. David Kupfer 181,488 Shares At $5.51/Share",2016-03-18 07:57:00-04:00,NERV,positive
895676.0,Minerva Neurosciences Reports Q4 EPS $(0.34) vs. (0.31),2016-03-14 07:32:00-04:00,NERV,neutral
895677.0,Minerva Neurosciences Announces Positive Topline Data From Phase 1B Clinical Trial With Min-202 For Major Depressive Disorder,2016-03-11 08:31:00-05:00,NERV,negative
895678.0,Minerva Reports Closing of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder,2016-02-22 08:32:00-05:00,NERV,negative
895679.0,Minerva Neurosciences MIN-202 Well-Tolerated in Phase I Clinical Study in Japanese Patients,2016-02-01 08:36:00-05:00,NERV,neutral
895680.0,UPDATE: Minerva Says FDA Accepted IND App for MIN-101; Closed Enrollment for Phase IIb Trial of MIN-101,2015-12-29 16:02:00-05:00,NERV,positive
895681.0,Minerva Neurosciences Announces Update on MIN-101 Clinical Development Program,2015-12-29 16:01:00-05:00,NERV,neutral
895682.0,"Minerva Achieves Enrollment Target in Phase IIb Trial With MIN-101, Met 234 Patient Target",2015-12-18 08:44:00-05:00,NERV,neutral
895683.0,Minerva Issues Year-End Update on Trials: Patient Enrollment Progress Confirms Timeline Expectations for Topline Data Availability from Four Trials in 1H'16,2015-12-09 08:33:00-05:00,NERV,positive
895684.0,Minerva Neurosciences Reports Q3 EPS $(0.24) vs. Est. $(0.36),2015-11-05 07:34:00-05:00,NERV,neutral
895685.0,"Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist",2015-09-24 08:32:00-04:00,NERV,negative
895686.0,Minerva Neurosciences Reports Q2 EPS $(0.27) vs. Est. $(0.41),2015-08-05 07:37:00-04:00,NERV,neutral
895687.0,Minerva Neurosciences Files for Up to $150M Mixed Shelf,2015-07-21 06:34:00-04:00,NERV,neutral
895688.0,"Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist",2015-06-16 07:31:00-04:00,NERV,negative
895689.0,Minerva Neurosciences Announces Appointment of Dr. Fouzia Laghrissi-Thode to Its Board of Directors,2015-05-18 07:32:00-04:00,NERV,neutral
895690.0,Minerva Neurosciences Files for Resale of 12.6M Shares by Selling Shareholders,2015-04-30 06:37:00-04:00,NERV,positive
895691.0,"Federated Investors Shows 18.2% Stake in Minerva Neurosciences, Increased From 0.12%",2015-04-09 12:51:00-04:00,NERV,positive
895692.0,Minerva Neurosciences Reports Q4 EPS -$0.40 Vs Est -$0.46,2015-03-26 16:02:00-04:00,NERV,neutral
895693.0,13D Filing Shows Minerva Neurosciences Holder Care Capital Cuts Stake From 15.6% In December To 9% Now,2015-03-25 16:24:00-04:00,NERV,positive
895694.0,"Minerva Neurosciences Director De Rubertis Buys 202,634 Shares @$4.81/Share -Form 4",2015-03-20 12:46:00-04:00,NERV,positive
895695.0,Minerva Neurosciences Announces Offering Of 6.28M Shares For $4.81/Share,2015-03-13 09:18:00-04:00,NERV,positive
895696.0,Morning Market Gainers,2015-01-22 09:48:00-05:00,NERV,neutral
895697.0,"Thursday's Morning Movers: Minerva, City National Pop 17% Higher",2015-01-22 09:15:00-05:00,NERV,neutral
895698.0,Why Minerva Neurosciences Is Trading Higher,2015-01-21 21:21:00-05:00,NERV,neutral
895699.0,"Wednesday's After-Hours Movers: eBay Pops 2%, American Express Drops 2%",2015-01-21 17:26:00-05:00,NERV,neutral
895700.0,Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202,2015-01-21 16:31:00-05:00,NERV,positive
895701.0,Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank,2015-01-20 16:01:00-05:00,NERV,negative
895702.0,Mid-Morning Market Update: Markets Open Higher; Commercial Metals Posts Upbeat Earnings,2015-01-06 10:46:00-05:00,NERV,neutral
895703.0,"Tuesday's Morning Market Movers: Minerva, El Pollo LoCo And More",2015-01-06 10:42:00-05:00,NERV,neutral
895704.0,Stocks Hitting 52-Week Highs,2015-01-06 10:23:00-05:00,NERV,neutral
895705.0,Morning Market Movers,2015-01-06 09:50:00-05:00,NERV,neutral
895706.0,Minerva Neurosciences Soars 60% Following Parkinson's Disease Treatment News,2015-01-06 09:21:00-05:00,NERV,neutral
895707.0,Benzinga's Top #PreMarket Gainers,2015-01-06 08:12:00-05:00,NERV,positive
895708.0,Monday's After-Hours Market Movers,2015-01-05 18:53:00-05:00,NERV,neutral
895709.0,Minerva Neurosciences Announces Data Shows Analog of Minerva's MIN-301 Compound Improves Symptoms Of Parkinson's Disease in Primates,2015-01-05 16:06:00-05:00,NERV,positive
895710.0,Minerva Neurosciences Appoints Remy Luthringer As CEO,2014-11-25 07:32:00-05:00,NERV,neutral
895711.0,rva Neurosciences Announces Completion Of FDA Review Of Investigational New Drug Application For MIN-202 And Plans For First U.S.-Based Clinical Trial,2014-09-22 08:32:00-04:00,NERV,neutral
895712.0,Benzinga's Top Initiations,2014-07-28 09:14:00-04:00,NERV,positive
895713.0,"JMP Securities Initiates Minerva Neurosciences At Market Perform, Shares Gain",2014-07-28 08:26:00-04:00,NERV,positive
895714.0,"JMP Securities Initiates Coverage on Minerva Neurosciences, Inc. at Market Perform, Announces $16.00 PT",2014-07-28 06:32:00-04:00,NERV,positive
895715.0,Shares of Minerva Neurosciences Moving Higher Following 13G Filing from J&J Showing 18% Stake in Co.,2014-07-17 11:00:00-04:00,NERV,positive
895716.0,Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer,2014-07-14 08:31:00-04:00,NERV,neutral
895717.0,Minerva Shares Rise 22% on Heavy Insider Buying,2014-07-10 11:50:00-04:00,NERV,positive
895718.0,Stocks Hitting 52-Week Lows,2014-07-07 10:12:00-04:00,NERV,negative
895719.0,Hunting The Next GoPro: Short Week Brings Up To 7 IPOs,2014-07-01 11:15:00-04:00,NERV,neutral
895720.0,"Minerva Neurosciences Shares Open for Trade at $6/Share, IPO Priced at $6",2014-07-01 10:50:00-04:00,NERV,positive
895721.0,Waiting on 3 IPOs This Morning,2014-07-01 08:14:00-04:00,NERV,neutral
895722.0,Waiting on 3 IPOs This Morning,2014-06-26 07:38:00-04:00,NERV,neutral
895723.0,IPO Lookout: IPOs Up Double Digits On The Week ,2014-06-20 16:09:00-04:00,NERV,neutral
